Isabel C Arrillaga-Romany (Isabel Arrillaga-Romany)

Publication Activity (10 Years)

Years Active: 2021-2024
Publications (10 Years): 29

Top Topics

Newly Diagnosed

Top Venues

Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Clinical cancer research : an official journal of the American Association for Cancer Research

This page only lists publications with an associated author ORCID identifier.

Publications

Isabel C Arrillaga-Romany, Sharon L Gardner, Yazmin Odia, Dolly Aguilera, Joshua E Allen, Tracy T Batchelor, Nicholas A Butowski, Clark C Chen, Timothy F Cloughesy, Andrew Cluster, John de Groot, Karan S Dixit, Jerome J Graber, Aya M Haggiagi, Rebecca A Harrison, Albert Kheradpour, Lindsay B Kilburn, Sylvia C Kurz, Guangrong Lu, Tobey J MacDonald, Minesh P Mehta, Allen S Melemed, Phioanh Leia Nghiemphu, Samuel C Ramage, Nicole A Shonka, Ashley L Sumrall, Rohinton S Tarapore, Lynne P Taylor, Yoshie Umemura, Patrick Yung Wen
ONC201 (Dordaviprone) in Recurrent H3 K27M-Mutant Diffuse Midline Glioma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2024)
Isabel C Arrillaga-Romany, Julie J Miller
Demonstrated efficacy and mechanisms of sensitivity of ONC201: H3K27M-mutant diffuse midline glioma in the spotlight. Neuro-oncology 26 (6) (2024)
Isabel C Arrillaga-Romany, Andrew Lassman, Susan L McGovern, Sabine Mueller, Burt Nabors, Martin van den Bent, Michael A Vogelbaum, Joshua E Allen, Allen S Melemed, Rohinton S Tarapore, Patrick Y Wen, Timothy Cloughesy
ACTION: a randomized phase 3 study of ONC201 (dordaviprone) in patients with newly diagnosed H3 K27M-mutant diffuse glioma. Neuro-oncology 26 (Supplement_2) (2024)
Isabel C Arrillaga-Romany, Julie J Miller
Demonstrated efficacy and mechanisms of sensitivity of ONC201: H3K27M-mutant diffuse midline glioma in the spotlight. Neuro-oncology 26 (6) (2024)
Yazmin Odia, Matthew D Hall, Timothy Francis Cloughesy, Patrick Y Wen, Isabel C Arrillaga-Romany, Doured Daghistani, Minesh P Mehta, Rohinton S Tarapore, Samuel C Ramage, Joshua E Allen
Selective DRD2 antagonist and ClpP agonist ONC201 in a recurrent non-midline H3 K27M-mutant glioma cohort. Neuro-oncology 26 (Supplement_2) (2024)
Matthew D Dun, Yazmin Odia, Isabel C Arrillaga-Romany
Diffuse midline glioma, H3K27-altered: Illuminating the dark side of the moon. Neuro-oncology 26 (Supplement_2) (2024)
Yazmin Odia, Matthew D Hall, Timothy Francis Cloughesy, Patrick Y Wen, Isabel C Arrillaga-Romany, Doured Daghistani, Minesh P Mehta, Rohinton S Tarapore, Samuel C Ramage, Joshua E Allen
Selective DRD2 Antagonist and ClpP Agonist ONC201 in a Recurrent Non-midline H3 K27M-mutant Glioma Cohort. Neuro-oncology (2024)
Isabel C Arrillaga-Romany, Sharon L Gardner, Yazmin Odia, Dolly Aguilera, Joshua E Allen, Tracy T Batchelor, Nicholas A Butowski, Clark C Chen, Timothy F Cloughesy, Andrew Cluster, John de Groot, Karan S Dixit, Jerome J Graber, Aya M Haggiagi, Rebecca A Harrison, Albert Kheradpour, Lindsay B Kilburn, Sylvia C Kurz, Guangrong Lu, Tobey J MacDonald, Minesh P Mehta, Allen S Melemed, Phioanh Leia Nghiemphu, Samuel C Ramage, Nicole A Shonka, Ashley L Sumrall, Rohinton S Tarapore, Lynne P Taylor, Yoshie Umemura, Patrick Yung Wen
ONC201 (Dordaviprone) in Recurrent H3 K27M-Mutant Diffuse Midline Glioma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2024)
Isabel C Arrillaga-Romany, Andrew Lassman, Susan L McGovern, Sabine Mueller, Burt Nabors, Martin van den Bent, Michael A Vogelbaum, Joshua E Allen, Allen S Melemed, Rohinton S Tarapore, Patrick Y Wen, Timothy Cloughesy
ACTION: a randomized phase 3 study of ONC201 (dordaviprone) in patients with newly diagnosed H3 K27M-mutant diffuse glioma. Neuro-oncology 26 (Supplement_2) (2024)
Yazmin Odia, Matthew D Hall, Timothy Francis Cloughesy, Patrick Y Wen, Isabel C Arrillaga-Romany, Doured Daghistani, Minesh P Mehta, Rohinton S Tarapore, Samuel C Ramage, Joshua E Allen
Selective DRD2 antagonist and ClpP agonist ONC201 in a recurrent non-midline H3 K27M-mutant glioma cohort. Neuro-oncology 26 (Supplement_2) (2024)
Isabel C Arrillaga-Romany, Sharon L Gardner, Yazmin Odia, Dolly Aguilera, Joshua E Allen, Tracy T Batchelor, Nicholas A Butowski, Clark C Chen, Timothy F Cloughesy, Andrew Cluster, John de Groot, Karan S Dixit, Jerome J Graber, Aya M Haggiagi, Rebecca A Harrison, Albert Kheradpour, Lindsay B Kilburn, Sylvia C Kurz, Guangrong Lu, Tobey J MacDonald, Minesh P Mehta, Allen S Melemed, Phioanh Leia Nghiemphu, Samuel C Ramage, Nicole A Shonka, Ashley L Sumrall, Rohinton S Tarapore, Lynne P Taylor, Yoshie Umemura, Patrick Yung Wen
ONC201 (Dordaviprone) in Recurrent H3 K27M-Mutant Diffuse Midline Glioma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 42 (13) (2024)
Isabel C Arrillaga-Romany, Julie J Miller
Demonstrated efficacy and mechanisms of sensitivity of ONC201: H3K27M-mutant diffuse midline glioma in the spotlight. Neuro-oncology 26 (6) (2024)
Yazmin Odia, Matthew D Hall, Timothy Francis Cloughesy, Patrick Y Wen, Isabel C Arrillaga-Romany, Doured Daghistani, Minesh P Mehta, Rohinton S Tarapore, Samuel C Ramage, Joshua E Allen
Selective DRD2 antagonist and ClpP agonist ONC201 in a recurrent non-midline H3 K27M-mutant glioma cohort. Neuro-oncology 26 (Supplement_2) (2024)
Isabel C Arrillaga-Romany, Andrew Lassman, Susan L McGovern, Sabine Mueller, Burt Nabors, Martin van den Bent, Michael A Vogelbaum, Joshua E Allen, Allen S Melemed, Rohinton S Tarapore, Patrick Y Wen, Timothy Cloughesy
ACTION: a randomized phase 3 study of ONC201 (dordaviprone) in patients with newly diagnosed H3 K27M-mutant diffuse glioma. Neuro-oncology 26 (Supplement_2) (2024)
Isabel C Arrillaga-Romany, Sharon L Gardner, Yazmin Odia, Dolly Aguilera, Joshua E Allen, Tracy T Batchelor, Nicholas A Butowski, Clark C Chen, Timothy F Cloughesy, Andrew Cluster, John de Groot, Karan S Dixit, Jerome J Graber, Aya M Haggiagi, Rebecca A Harrison, Albert Kheradpour, Lindsay B Kilburn, Sylvia C Kurz, Guangrong Lu, Tobey J MacDonald, Minesh P Mehta, Allen S Melemed, Phioanh Leia Nghiemphu, Samuel C Ramage, Nicole A Shonka, Ashley L Sumrall, Rohinton S Tarapore, Lynne P Taylor, Yoshie Umemura, Patrick Yung Wen
ONC201 (Dordaviprone) in Recurrent H3 K27M-Mutant Diffuse Midline Glioma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 42 (13) (2024)
Isabel C Arrillaga-Romany, Julie J Miller
Demonstrated efficacy and mechanisms of sensitivity of ONC201: H3K27M-mutant diffuse midline glioma in the spotlight. Neuro-oncology (2024)
Yazmin Odia, Matthew D Hall, Timothy Francis Cloughesy, Patrick Y Wen, Isabel C Arrillaga-Romany, Doured Daghistani, Minesh P Mehta, Rohinton S Tarapore, Samuel C Ramage, Joshua E Allen
Selective DRD2 antagonist and ClpP agonist ONC201 in a recurrent non-midline H3 K27M-mutant glioma cohort. Neuro-oncology 26 (Supplement_2) (2024)
Isabel C Arrillaga-Romany, Andrew Lassman, Susan L McGovern, Sabine Mueller, Burt Nabors, Martin van den Bent, Michael Vogelbaum, Joshua E Allen, Allen S Melemed, Rohinton S Tarapore, Patrick Y Wen, Timothy Cloughesy
ACTION: A randomized phase 3 study of ONC201 (dordaviprone) in patients with newly diagnosed H3 K27M-mutant diffuse glioma. Neuro-oncology (2024)
Isabel C Arrillaga-Romany, Sharon L Gardner, Yazmin Odia, Dolly Aguilera, Joshua E Allen, Tracy T Batchelor, Nicholas A Butowski, Clark C Chen, Timothy F Cloughesy, Andrew Cluster, John de Groot, Karan S Dixit, Jerome J Graber, Aya M Haggiagi, Rebecca A Harrison, Albert Kheradpour, Lindsay B Kilburn, Sylvia C Kurz, Guangrong Lu, Tobey J MacDonald, Minesh P Mehta, Allen S Melemed, Phioanh Leia Nghiemphu, Samuel C Ramage, Nicole A Shonka, Ashley L Sumrall, Rohinton S Tarapore, Lynne P Taylor, Yoshie Umemura, Patrick Yung Wen
ONC201 (Dordaviprone) in Recurrent H3 K27M-Mutant Diffuse Midline Glioma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 42 (13) (2024)
Matthew D Dun, Yazmin Odia, Isabel C Arrillaga-Romany
Diffuse midline glioma, H3K27-altered: Illuminating the dark side of the moon. Neuro-oncology 26 (Supplement_2) (2024)
Isabel C Arrillaga-Romany, Andrew Lassman, Susan L McGovern, Sabine Mueller, Burt Nabors, Martin van den Bent, Michael A Vogelbaum, Joshua E Allen, Allen S Melemed, Rohinton S Tarapore, Patrick Y Wen, Timothy Cloughesy
ACTION: a randomized phase 3 study of ONC201 (dordaviprone) in patients with newly diagnosed H3 K27M-mutant diffuse glioma. Neuro-oncology 26 (Supplement_2) (2024)
Matthew D Dun, Yazmin Odia, Isabel C Arrillaga-Romany
Diffuse midline glioma, H3K27-altered: Illuminating the dark side of the moon. Neuro-oncology 26 (Supplement_2) (2024)
K Ina Ly, Leland G K Richardson, Mofei Liu, Alona Muzikansky, Jonathan Cardona, Kevin Lou, Andrew L Beers, Ken Chang, James M Brown, Xiaoyue Ma, David A Reardon, Isabel C Arrillaga-Romany, Deborah A Forst, Justin T Jordan, Eudocia Quant Lee, Jorg Dietrich, Lakshmi Nayak, Patrick Yung Wen, Ugonma N Chukwueke, Anita Giobbie-Hurder, Bryan D Choi, Tracy T Batchelor, Jayashree Kalpathy-Cramer, William T Curry, Elizabeth R Gerstner
Bavituximab decreases immunosuppressive myeloid-derived suppressor cells in newly diagnosed glioblastoma patients. Clinical cancer research : an official journal of the American Association for Cancer Research (2023)
Rifaquat Rahman, Lorenzo Trippa, Eudocia Quant Lee, Isabel C Arrillaga-Romany, Geoffrey Fell, Mehdi Touat, Christine McCluskey, Jennifer Wiley, Sarah Gaffey, Jan Drappatz, Mary R Welch, Evanthia Galanis, Manmeet S Ahluwalia, Howard Colman, Louis Burt Nabors, Jaroslaw Hepel, Heinrich Elinzano, David Schiff, Ugonma N Chukwueke, Rameen Beroukhim, Lakshmi Nayak, J Ricardo McFaline-Figueroa, Tracy T Batchelor, Mikael L Rinne, Thomas J Kaley, Christine Lu-Emerson, Ingo K Mellinghoff, Wenya Linda Bi, Omar Arnaout, Pier Paolo Peruzzi, Daphne A Haas-Kogan, Shyam Tanguturi, Daniel Cagney, Ayal A Aizer, Lisa Doherty, Maria Lavallee, Brittany Fisher-Longden, Shanna Dowling, Jack Geduldig, Fiona Watkinson, William Pisano, Seth Malinowski, Shakti Ramkissoon, Sandro Santagata, David M Meredith, E Antonio Chiocca, David A Reardon, Brian M Alexander, Keith L Ligon, Patrick Yung Wen
Inaugural Results of the Individualized Screening Trial of Innovative Glioblastoma Therapy: A Phase II Platform Trial for Newly Diagnosed Glioblastoma Using Bayesian Adaptive Randomization. Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2023)
Sriram Venneti, Abed Rahman Kawakibi, Sunjong Ji, Sebastian M Waszak, Stefan R Sweha, Mateus Mota, Matthew Pun, Akash Deogharkar, Chan Chung, Rohinton S Tarapore, Samuel Ramage, Andrew S Chi, Patrick Yung Wen, Isabel C Arrillaga-Romany, Tracy T Batchelor, Nicholas A Butowski, Ashley L Sumrall, Nicole A Shonka, Rebecca A Harrison, John de Groot, Minesh P Mehta, Matthew D Hall, Doured Daghistani, Timothy F Cloughesy, Benjamin M Ellingson, Kevin Beccaria, Pascale Varlet, Michelle M Kim, Yoshie Umemura, Hugh J L Garton, Andrea T Flynn, Jonathan Schwartz, Rajan Jain, Maureen Kachman, Heidi Baum, Charles F Burant, Sophie L Mottl, Rodrigo T Cartaxo, Vishal John, Dana Messinger, Tingting Qin, Erik R Peterson, Peter Sajjakulnukit, Karthik Ravi, Alyssa Waugh, Dustin Walling, Yujie Ding, Ziyun Xia, Anna A Schwendeman, Debra Hawes, Fusheng Yang, Alexander R Judkins, Daniel R Wahl, Costas Andreas Lyssiotis, Daniel de la Nava, Marta Marija Alonso, Augustine Eze, Jasper Spitzer, Susanne Viktoria Schmidt, Ryan J Duchatel, Matthew D Dun, Jason E Cain, Li Jiang, Sylwia A Stopka, Gerard Baquer, Michael S Regan, Mariella G Filbin, Nathalie Y R Agar, Lili Zhao, Chandan Kumar-Sinha, Rajen J Mody, Arul M Chinnaiyan, Ryo Kurokawa, Sriram Venneti, Viveka N Yadav, Jacques Grill, Cassie N Kline, Romain Mueller, Adam C Resnick, Javad Nazarian, Joshua E Allen, Yazmin Odia, Sharon L Gardner, Carl J Koschmann
Clinical efficacy of ONC201 in H3K27M-mutant diffuse midline gliomas is driven by disruption of integrated metabolic and epigenetic pathways. Cancer discovery (2023)
Julie J Miller, Isabel C Arrillaga-Romany
IDH-mutant glioma: A new IDH1 inhibitor moves forward. Neuro-oncology 25 (2) (2023)
Matthew D Dun, Yazmin Odia, Isabel C Arrillaga-Romany
Diffuse midline glioma, H3K27-altered: Illuminating the dark side of the moon. Neuro-oncology (2023)
Julie J Miller, Isabel C Arrillaga-Romany
IDH-mutant glioma: A new IDH1 inhibitor moves forward. Neuro-oncology (2022)
Mohamed Ehab El-Abtah, Michael R Wenke, Pratik Talati, Melanie Fu, Daniel Kim, Akila Weerasekera, Julian He, Anna Vaynrub, Mark G Vangel, Otto Rapalino, Ovidiu Andronesi, Isabel C Arrillaga-Romany, Deborah A Forst, Yi-Fen Yen, Bruce R Rosen, Tracy T Batchelor, Ramon Gilberto González, Jorg Dietrich, Elizabeth R Gerstner, Eva-Maria Ratai
Myo-Inositol Levels Measured with MR Spectroscopy Can Help Predict Failure of Antiangiogenic Treatment in Recurrent Glioblastoma. Radiology (2021)